Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
AXS-05 in Alzheimer’s disease agitation data featured in oral plenary session
New data for AXS-07 in migraine demonstrating efficacy in pooled analysis
Presentations on cognitive and wake promoting effects of solriamfetol
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations highlighting its innovative psychiatry and neurology pipeline at the American Academy of Neurology (AAN) 2024 annual meeting, being held April 13-18, 2024, in Denver, Colorado. The presentations include an oral presentation during the Clinical Trials Plenary Session of data from the ACCORD Phase 3 trial of AXS-05 in Alzheimer’s disease agitation (ADA). Presentations related to the AXS-07 clinical program in migraine include new pooled efficacy data from the MOMENTUM and INTERCEPT Phase 3 trials. Additionally, there will be data presentations on cognition and sleep from the solriamfetol clinical program.
Details for the presentations are as follows:
Alzheimer’s Disease Agitation
Title: Efficacy and Safety Of AXS-05 in Agitation Associated with Alzheimer’s Disease: Results From ACCORD, a Phase 3, Double-Blind, Placebo-Controlled, Relapse Prevention
Trial
Presentation Date and Time: Tuesday, April 16 from 9:15 a.m. to 11:30 a.m. Mountain Time
Lead Author: Anton P. Porsteinsson, MD, William B. and Sheila Konar Professor of Psychiatry at the University of Rochester, School of Medicine and Dentistry
Session Name: PL5: Clinical Trials Plenary Session
Program Number: PL5.005
Lesen Sie auch
Migraine
Title: Combined Efficacy and Safety of AXS-07 (MOSEICTM Meloxicam and Rizatriptan) in Two Phase 3 Clinical Trials
Presentation Date and Time: Tuesday, April 16 from 11:45 a.m. to 12:45 p.m. Mountain Time
Lead Author: Stewert Tepper, MD, Professor of Neurology at the Geisel School of Medicine at Dartmouth
Session Name: P7: Headache: Therapeutics 2
Program Number: P7.002
Title: EMERGE Study: An Open-label Evaluation of the Efficacy and Safety of AXS-07 (MoSEIC meloxicam-rizatriptan) for Migraine in Adults with Prior Inadequate Response to an Oral
CGRP Inhibitor
Presentation Date and Time: Tuesday, April 16 from 8 a.m. to 9 a.m. Mountain Time
Lead Author: Peter McAllister, MD, Director of the New England Center for Neurology and Headache
Session Name: P6: Headache: Therapeutics 1
Program Number: P6.006
Cognition
Title: Solriamfetol Improves Cognitive Performance in Preclinical Models of Sleep Apnea and in a Randomized Placebo-controlled Study of Sleep Apnea Participants (SHARP)